Monash IVF Group Ltd (ASX: MVF) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Monash IVF Group Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $566.92 million
P/E Ratio 23.55
Dividend Yield 3.22%
Shares Outstanding 389.63 million
Earnings per share 0.062
Dividend per share 0.05
Year To Date Return 14.23%
Earnings Yield 4.25%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Monash IVF Group Ltd (ASX: MVF)
    Latest News

    ASX healthcare digital disruption woman has medical consultation appointment video video call with her doctor.
    Healthcare Shares

    ASX healthcare shares could be next to be hit by the digital disruption

    You might think ASX healthcare shares would be among the most insulated from the digital disruption, but that view doesn’t…

    Read more »

    Share Gainers

    Monash IVF (ASX:MVF) share price jumps on profit growth and dividend restart

    The Monash IVF Group Ltd (ASX: MVF) share price is bucking the market downtrend after it posted its profit results…

    Read more »

    Share Fallers

    Why Costa, Monash IVF, Newcrest, & Xero shares are dropping lower

    Costa Group Holdings Ltd (ASX:CGC) and Newcrest Mining Ltd (ASX:NCM) shares are two of four dropping lower on Monday...

    Read more »

    Share Fallers

    Why BetMakers, Flight Centre, Monash IVF, & Sydney Airport are dropping lower

    Flight Centre Travel Group Ltd (ASX:FLT) and Monash IVF Group Ltd (ASX:MVF) shares are two of four dropping lower today...

    Read more »

    Share Fallers

    Why Mesoblast, Monash IVF, Netwealth, & Reece shares are dropping lower

    Monash IVF Group Ltd (ASX:MVF) and Reece Ltd (ASX:REH) shares are two of four dropping lower today...

    Read more »

    Share Fallers

    Monash IVF (ASX:MVF) share price lower despite forecasting strong earnings growth

    The Monash IVF Group Ltd (ASX:MVF) share price is trading lower despite forecasting strong earnings growth in the first half...

    Read more »

    Share Fallers

    Why G8 Education, Monash IVF, NIB, & Uniti shares are dropping lower

    G8 Education Ltd (ASX:GEM) and NIB Holdings Limited (ASX:NHF) shares are two of four dropping lower on Monday. Here's why...

    Read more »

    wooden blocks printed with the letters IVF signifying Monash IVF share price
    Share Market News

    Monash IVF share price drops 10% on annual result

    The Monash IVF share price is 10% lower after the company released its annual result for the year to 30…

    Read more »

    Share Market News

    Fund managers have been buying these ASX shares

    Fund managers have been buying Marley Spoon AG (ASX:MMM) this month. Here's what you need to know...

    Read more »

    Cheap Shares

    The latest ASX shares that brokers are urging you to buy today

    The ASX 200 remains among the best places to generate wealth in the post COVID-19 world. Here are two stocks…

    Read more »

    a woman
    Share Fallers

    Why Beach, Mesoblast, Monash IVF, & Select Harvests are tumbling lower

    Mesoblast limited (ASX:MSB) and Monash IVF Group Ltd (ASX:MVF) shares are two of four tumbling lower on Tuesday...

    Read more »

    a woman
    Healthcare Shares

    2 ASX healthcare shares that were smashed in March

    March was brutal for ASX investors, with Ramsay Health Care Limited (ASX: RHC) and this ASX healthcare share providing no relief.

    Read more »

    Frequently Asked Questions

    Yes, Monash IVF Group has historically paid two fully franked shareholder dividends a year.

    Monash IVF Group generally pays its shareholder dividends in April and October. 

    Monash IVF Group listed on the ASX on 26 June 2014.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    07 Mar 2024 $0.0250 100.00% Interim 05 Apr 2024
    07 Sep 2023 $0.0220 100.00% Final 11 Oct 2023
    08 Mar 2023 $0.0220 100.00% Interim 06 Apr 2023
    08 Sep 2022 $0.0220 100.00% Final 07 Oct 2022
    07 Mar 2022 $0.0220 100.00% Interim 04 Apr 2022
    09 Sep 2021 $0.0210 100.00% Final 08 Oct 2021
    09 Mar 2021 $0.0210 100.00% Interim 07 Apr 2021
    05 Mar 2020 $0.0210 100.00% Interim 02 Oct 2020
    05 Sep 2019 $0.0300 100.00% Final 11 Oct 2019
    06 Sep 2018 $0.0260 100.00% Final 12 Oct 2018
    08 Mar 2018 $0.0340 100.00% Interim 06 Apr 2018
    06 Sep 2017 $0.0000 100.00% Final 13 Oct 2017
    02 Mar 2017 $0.0430 100.00% Interim 07 Apr 2017
    06 Sep 2016 $0.0450 100.00% Final 14 Oct 2016
    08 Mar 2016 $0.0400 100.00% Interim 08 Apr 2016

    MVF ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Monash IVF Group Ltd

    Monash IVF Group Ltd (ASX: MVF) is a specialist assisted reproductive services provider. The company offers fertility treatments and specialist diagnostic obstetric and gynaecological ultrasound services. Monash is among the leading providers of assisted reproductive services in Australia and Malaysia. It also has a cooperative agreement with a hospital in China. 

    MVF Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    27 Mar 2024 $1.46 $0.00 0.00% 593,348 $1.44 $1.47 $1.44
    26 Mar 2024 $1.46 $0.03 2.10% 2,186,907 $1.43 $1.46 $1.41
    25 Mar 2024 $1.43 $0.00 0.00% 388,640 $1.45 $1.45 $1.41
    22 Mar 2024 $1.43 $-0.03 -2.05% 674,975 $1.46 $1.47 $1.43
    21 Mar 2024 $1.46 $0.02 1.39% 1,392,221 $1.45 $1.47 $1.43
    20 Mar 2024 $1.44 $0.02 1.41% 559,939 $1.42 $1.44 $1.42
    19 Mar 2024 $1.42 $-0.01 -0.70% 628,130 $1.44 $1.44 $1.40
    18 Mar 2024 $1.43 $-0.02 -1.38% 350,530 $1.47 $1.47 $1.43
    15 Mar 2024 $1.45 $-0.01 -0.68% 13,096,794 $1.46 $1.48 $1.45
    14 Mar 2024 $1.46 $-0.03 -2.01% 808,065 $1.47 $1.50 $1.46
    13 Mar 2024 $1.49 $0.03 2.05% 1,448,286 $1.48 $1.50 $1.48
    12 Mar 2024 $1.46 $0.02 1.39% 747,224 $1.46 $1.47 $1.44
    11 Mar 2024 $1.44 $-0.06 -4.01% 639,922 $1.48 $1.50 $1.43
    08 Mar 2024 $1.50 $0.03 2.04% 815,675 $1.47 $1.50 $1.47
    07 Mar 2024 $1.47 $-0.02 -1.34% 1,198,518 $1.49 $1.49 $1.47
    06 Mar 2024 $1.49 $0.02 1.36% 767,221 $1.48 $1.50 $1.47
    05 Mar 2024 $1.47 $0.02 1.38% 3,256,587 $1.45 $1.48 $1.45
    04 Mar 2024 $1.45 $0.01 0.69% 437,879 $1.46 $1.47 $1.43
    01 Mar 2024 $1.44 $-0.04 -2.70% 621,376 $1.49 $1.49 $1.44
    29 Feb 2024 $1.48 $0.01 0.68% 918,058 $1.47 $1.49 $1.47
    28 Feb 2024 $1.47 $0.01 0.69% 438,900 $1.46 $1.47 $1.43
    27 Feb 2024 $1.46 $0.02 1.39% 628,109 $1.46 $1.46 $1.44

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    29 Nov 2023 Michael Knaap Issued 517,433 $657,139
    Issue of securities. 2,017,827 - Performance Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Zita Peach Non-Executive Director Oct 2016
    Ms Peach has more than 25 years of commercial experience in the pharmaceutical, biotechnology, medical devices and health services industries, and has worked for industry players such as CSL Limited and Merck Sharp & Dohme, the Australian subsidiary of Merck Inc. Zita's most recent executive position is Managing Director for Australia and New Zealand and Executive Vice President, South Asia Pacific for Fresenius Kabi, a provider of pharmaceutical products and medical devices to hospitals. Previously, Zita was Vice President, Business Development, for CSL Limited, a position she held for ten years. Ms Peach is Non-Executive Director of two private company boards, Icon Group Pty Ltd and Nucleus Network Pty Ltd. Zita is also a member of the Hudson Institute of Medical Research Board.
    Mr Josef Jerzy Czyzewski Non-Executive Director Jun 2014
    Mr. Czyzewski has over 30 years of experience in finance positions and experience in the health industry. Josef has held the positions of CFO at Healthscope Limited, and more recently CFO/General Manager Strategy and Development at Spotless Group Limited following its takeover by private equity interests in 2012. Prior to that time, Josef had held various senior finance positions with BHP Billiton including VP Finance and Corporate Treasurer.
    Mr Richard Hugh Davis Non-Executive ChairmanNon-Executive Director Jun 2014
    Mr. Davis worked for InvoCare for 20 years until 2008. For the majority of that time he held the position of CEO and managed the growth of that business through a number of ownership changes and over 20 acquisitions, including offshore in Singapore. Prior to InvoCare Limited, Richard worked as an accounting partner of Bird Cameron.
    Mr Neil John Broekhuizen Non-Executive Director Jun 2014
    Mr. Broekhuizen is the Joint Chief Executive Officer of Ironbridge. Neil has over 30 years of experience in the finance industry, including 28 years in private equity with Investcorp and Bridgepoint in Europe and Ironbridge in Australia. He has sat on the Ironbridge Investment Committee since inception.
    Mr Michael Damian Knaap Chief Executive OfficerManaging Director Sep 2015
    Mr Knaap has nearly 30 years of experience in executive positions with a financial, operational, strategic and leadership background in Healthcare and FMCG industries. Prior to joining MVF Group, Michael was with Patties Foods Limited where he held a number of executive positions over six years, including the role of Chief Financial Officer and Company Secretary.
    Dr Richard Charles Henshaw Executive Director Apr 2014
    Dr Henshaw MD FRANZCOG FRCOG has practiced in the field of reproductive medicine since 1995. Richard has served on many national bodies, including RANZCOG Council, the IVF Medical Directors Group of Australia and New Zealand, and the Reproductive Technology Accreditation Committee.
    Ms Catherine Jane West Non-Executive Director Sep 2020
    Ms West has over 25 years of legal, business affairs and strategy experience in customer focused businesses in the media, entertainment, telecommunications and medical sectors in Australia, the UK and Europe. Catherine is also a non-executive director of Peter Warren Automotive Group where she is also Chair of the People and Remuneration Committee and a member of the Audit and Risk Committee. In addition, she is a director of the Sydney Breast Cancer Foundation Limited, a director of the NIDA Foundation, the National Institute of Dramatic Art and a Chair of the Board of Governors of Wenona School. She was previously on the board of Southern Phone, a regional telecommunications company, before its sale to AGL. Catherine is also a consultant to the healthcare sector and to media companies internationally.
    Ms Catherine (Cathy) Ann Aston Non-Executive Director Feb 2024
    Ms Aston executive roles were in the telecommunications industry, predominantly at Telstra where she worked for over 20 years. During her time at Telstra her senior roles were varied, initially focussing on finance, and over time transitioning to strategic roles across marketing, customer experience and technology. Cathy has experience in international expansion, in particularly in Asia, having worked in Hong Kong, Sri Lanka and India. Over the past decade Cathy has been very active in non-executive and advisory roles. Cathy is a non executive director of ASX listed Integrated Research (Chair of the Audit and Risk Committee), IVE Group (Chair of the Risk and Compliance Committee), Macquarie Investment Management (Chair of the Audit, Risk and Compliance Committee) and IMB Bank (Chair). Previously she was on the Board of Virtus Health. Cathy advisory roles have included work with the NSW State Government, and an Advisory Board Member of Avanseus, a Singapore based AI business.
    Mr Malik Jainudeen Chief Financial OfficerCompany Secretary Apr 2019
    -
    Malik Jainudeen Chief Financial OfficerCompany Secretary
    -
    Hamish Hamilton Chief Operations Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited 83,516,281 21.43%
    Citicorp Nominees Pty Limited 59,749,303 15.33%
    J P Morgan Nominees Australia Pty Limited 49,255,781 12.64%
    National Nominees Limited 34,190,551 8.78%
    Argo Investments Limited 19,982,646 5.13%
    Washington H Soul Pattinson And Company Limited 17,725,000 4.55%
    UBS Nominees Pty Ltd 10,168,382 2.61%
    BNP Paribas Nominees Pty Ltd <Agency Lending DRP A/C> 6,861,358 1.76%
    HSBC Custody Nominees (Australia) Limited A/C 2 3,355,128 0.86%
    Pacific Custodians Pty Limted <Ordinary Unit Tst A/C> 2,474,369 0.64%
    Neweconomy com au Nominees Pty Limited <900 Account> 2,465,635 0.63%
    Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 2,429,696 0.62%
    Ippoliti Pty Ltd <Ippoliti Family Trust A/C> 2,011,336 0.52%
    BNP Paribas Nominees Pty Ltd <IB AU Noms Retail Client DRP> 1,556,240 0.40%
    Mr Prashant Nadkarni 1,461,484 0.38%
    Vollenhoven Investment Pty Ltd <Vollenhoven Family A/C> 1,447,787 0.37%
    Mclachlan Future Fund Pty Ltd <R & E Mclachlan S/F A/C> 1,385,944 0.36%
    Bnp Paribas Noms Pty Ltd <Drp> 1,311,952 0.34%
    Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> 1,285,310 0.33%
    Ong Administration Pty Ltd <The Ong Family Trust A/C> 1,201,906 0.31%

    Profile

    since

    Note